- Home
- NUWE vs RDHL Comparison
NUWE vs RDHL Comparison
Compare NUWE & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- RDHL
- Stock Information
- Founded
- NUWE 1999
- RDHL 2009
- Country
- NUWE United States
- RDHL Israel
- Employees
- NUWE N/A
- RDHL N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- RDHL Health Care
- Exchange
- NUWE Nasdaq
- RDHL Nasdaq
- Market Cap
- NUWE 3.9M
- RDHL 4.3M
- IPO Year
- NUWE N/A
- RDHL N/A
- Fundamental
- Price
- NUWE $6.88
- RDHL $2.15
- Analyst Decision
- NUWE Strong Buy
- RDHL
- Analyst Count
- NUWE 1
- RDHL 0
- Target Price
- NUWE $714.00
- RDHL N/A
- AVG Volume (30 Days)
- NUWE 121.9K
- RDHL 18.4K
- Earning Date
- NUWE 08-12-2025
- RDHL 08-28-2025
- Dividend Yield
- NUWE N/A
- RDHL N/A
- EPS Growth
- NUWE N/A
- RDHL N/A
- EPS
- NUWE N/A
- RDHL N/A
- Revenue
- NUWE $8,787,000.00
- RDHL $8,042,999.00
- Revenue This Year
- NUWE $6.53
- RDHL $381.91
- Revenue Next Year
- NUWE $51.63
- RDHL N/A
- P/E Ratio
- NUWE N/A
- RDHL N/A
- Revenue Growth
- NUWE N/A
- RDHL 23.17
- 52 Week Low
- NUWE $6.73
- RDHL $1.71
- 52 Week High
- NUWE $197.40
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- NUWE 25.34
- RDHL 64.10
- Support Level
- NUWE $7.20
- RDHL $2.00
- Resistance Level
- NUWE $10.08
- RDHL $2.08
- Average True Range (ATR)
- NUWE 0.99
- RDHL 0.09
- MACD
- NUWE 0.64
- RDHL 0.03
- Stochastic Oscillator
- NUWE 10.66
- RDHL 100.00
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.